Free Trial

Brokers Offer Predictions for 908 Devices FY2027 Earnings

908 Devices logo with Medical background

908 Devices Inc. (NASDAQ:MASS - Free Report) - Leerink Partnrs issued their FY2027 earnings estimates for 908 Devices in a report issued on Thursday, July 17th. Leerink Partnrs analyst P. Souda forecasts that the company will post earnings of ($0.45) per share for the year. The consensus estimate for 908 Devices' current full-year earnings is ($1.99) per share.

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of 908 Devices in a research report on Saturday, July 12th. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $5.33.

Read Our Latest Analysis on MASS

908 Devices Trading Up 1.4%

MASS traded up $0.10 during trading hours on Friday, hitting $6.88. The company's stock had a trading volume of 89,016 shares, compared to its average volume of 1,739,297. The business's 50-day moving average price is $6.32 and its 200-day moving average price is $4.46. 908 Devices has a 12 month low of $1.81 and a 12 month high of $8.06. The stock has a market cap of $246.54 million, a price-to-earnings ratio of -12.73 and a beta of 0.38.

908 Devices (NASDAQ:MASS - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.05. 908 Devices had a negative net margin of 28.80% and a negative return on equity of 27.10%. The firm had revenue of $11.78 million for the quarter, compared to the consensus estimate of $11.90 million.

Insider Activity

In other news, insider Michael S. Turner sold 7,148 shares of the business's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $7.51, for a total transaction of $53,681.48. Following the completion of the sale, the insider directly owned 1,373 shares of the company's stock, valued at approximately $10,311.23. The trade was a 83.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Joseph H. Iv Griffith sold 6,940 shares of the company's stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $7.08, for a total transaction of $49,135.20. Following the completion of the sale, the chief financial officer directly owned 102,930 shares of the company's stock, valued at approximately $728,744.40. This trade represents a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,543 shares of company stock valued at $233,890. 23.70% of the stock is currently owned by company insiders.

Institutional Trading of 908 Devices

Hedge funds have recently modified their holdings of the company. AWM Investment Company Inc. increased its holdings in shares of 908 Devices by 210.6% during the first quarter. AWM Investment Company Inc. now owns 5,199,924 shares of the company's stock valued at $23,296,000 after acquiring an additional 3,526,000 shares in the last quarter. First Light Asset Management LLC acquired a new position in shares of 908 Devices during the first quarter valued at about $7,621,000. Invesco Ltd. acquired a new position in shares of 908 Devices during the first quarter valued at about $2,910,000. Essex Investment Management Co. LLC acquired a new position in shares of 908 Devices during the first quarter valued at about $2,153,000. Finally, Legato Capital Management LLC acquired a new position in shares of 908 Devices during the first quarter valued at about $638,000. 88.06% of the stock is owned by hedge funds and other institutional investors.

908 Devices Company Profile

(Get Free Report)

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.

Further Reading

Earnings History and Estimates for 908 Devices (NASDAQ:MASS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in 908 Devices Right Now?

Before you consider 908 Devices, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 908 Devices wasn't on the list.

While 908 Devices currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It
NVDA Greenlight: China Sales Spark 50% Rally Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines